# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both mono...
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that ...
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48...